Pre-treatment levels of ctDNA may be useful in future clinical trials to predict long-term survival
COVAX cuts global COVID vaccine supply estimates by a quarter
13 September 2021UK Covid policies may have disproportionally impacted ethnic minorities at the end of life
13 September 2021Pre-treatment levels of ctDNA may be useful in future clinical trials to predict long-term survival
Pre-treatment circulating tumor (ct)DNA levels more accurately predicted long-term survival than classical survival surrogates in the NADIM study and might be useful for the design of new clinical trials, according to research presented today at the IASLC 2021 World Conference on Lung Cancer. The study was presented in today’s OA20: Exploring Treatment Modalities and Tools in Locally Advanced NSCLC.
